PBS updates

Venclexta (Venetoclax)

venetoclax 100 mg tablet, 120 · ORAL · PBS code 15358H

AUTHORITY_REQUIRED

What it costs

AU$7241.87 PBS-determined price per 120 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2026-06-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)


Second and final continuing treatment (treatment cycles 9 to 14 inclusive) of first-line therapy with acalabrutinib


Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

The treatment must be in combination with acalabrutinib; AND

The treatment must not be in combination with obinutuzumab; AND

The treatment must not exceed 12 cycles in total with this drug, measured from the initial dose, or, must not extend beyond disease progression, whichever comes first.

Sponsor: AbbVie Pty Ltd ABN 48 156 384 262

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.